Navigation Links
PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Date:9/18/2008

ANNAPOLIS, Md., Sept. 18 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will present two poster presentations and an oral presentation on its Protexia(R) and Valortim(R) medical countermeasures programs at the upcoming HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 / BARDA Industry Day, being held in Alexandria, VA September 24 -26, 2008.

Protexia(R), a recombinant version of human butyrylcholinesterase (BChE), is being developed as a pre- and post-exposure therapy for casualties on the battlefield or civilian victims of nerve agent attacks. Valortim(R), in co-development with Medarex, Inc., is a fully human monoclonal antibody designed to treat and protect against inhalational anthrax.

The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 and BARDA Industry Day will bring together public and private sector stakeholders for a dynamic dialogue on the current state of medical countermeasure preparedness, PHEMCE initiatives in the past year, and plans for moving forward to enhance national capabilities to respond to a public health emergency.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) - a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) - a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve

agents

-- RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
2. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
3. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
4. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
5. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
6. PharmAthene Reports First Quarter 2008 Financial Results
7. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
8. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
9. PharmAthene Reports Year-End 2007 Financial Results
10. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Dovetail Genomics™ LLC today announced that ... for a planned metagenomic genome assembly service. Richard ... genome assembly method in a talk on Friday, February ... Technology conference in Orlando, Fla. ... datasets is difficult. Using its proprietary Chicago ...
(Date:2/11/2016)... ... , ... Global Stem Cells Group, has announced ... new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, focusing ... The new GSCG clinic is headed by four prominent Ecuadorian physicians, including Pablo ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing a ... Management Companies (AMC) the option of joining or renewing ... fee determined by staff size, every employee in any ... ASAE and reap all available member benefits.   ... new organizational membership options will allow organizations of any ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark ... today the promotion of two long-standing principal investigators (PI) to the roles of ... Research and Development. , Dr. Laurence Chu, a Benchmark Research PI in the ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Technology Enhancements Accelerate Growth of ... of the digital and computed radiography markets in ... and Indonesia (TIM). It provides ... size, as well as regional market drivers and restraints. ... market penetration and market attractiveness, both for digital and ...
(Date:2/1/2016)... -- Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of a new ... Las Vegas , where Joey appeared at the ... Las Vegas , where Joey appeared at the Wocket booth to ... was filmed at the Consumer Electronics Show (CES2016) in Las ... and greet fans. --> --> ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):